Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04940390 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Satsuma Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,591
- Enrollment target
NCT04940390 is a Phase 3 study that has completed, run by Satsuma Pharmaceuticals. The registered enrollment target is 1,591 participants.
The verdict
NCT04940390, a Phase 3 study, has completed, sponsored by Satsuma Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,591 participants
- Enrollment target
Study Summary
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Interventions
- DRUG Placebo
- DRUG Dihydroergotamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,591 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2022-10-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04940390
The ClinicalTrials.gov registry entry for NCT04940390 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,591 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Satsuma Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04940390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04940390 about?
NCT04940390 is a clinical study titled "A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine". Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
What is the current status of trial NCT04940390?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,591 participants. The study started on 2021-06-30. Estimated completion is 2022-10-26.
What interventions are being tested in trial NCT04940390?
The interventions under investigation include: Placebo (DRUG), Dihydroergotamine (DRUG).
Who is sponsoring clinical trial NCT04940390?
This trial is sponsored by Satsuma Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.